Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
Inhibrx, Inc. shareholders will receive per share consideration of $30 per share in cash, a CVR equal to $5, plus 0.25 shares in New Inhibrx, a new publicly traded company that retains all non-101 assets of Inhibrx, Inc.
Related news for (INBX)
- Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President
- Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer
- Inhibrx Biosciences Announces Loan Agreement with Oxford Finance
- Inhibrx Biosciences Reports Third Quarter 2024 Financial Results
- SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates INBX, KAMN, BATL